fludarabine has been researched along with cladribine in 203 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.49) | 18.7374 |
1990's | 78 (38.42) | 18.2507 |
2000's | 79 (38.92) | 29.6817 |
2010's | 43 (21.18) | 24.3611 |
2020's | 2 (0.99) | 2.80 |
Authors | Studies |
---|---|
Clayton, SD; Montgomery, JA; Riordan, JM; Secrist, JA; Shortnacy-Fowler, AT | 1 |
Cristalli, G; Esker, JL; Jacobson, KA; Ji, XD; Melman, N; Olah, ME; Schneller, SW; Secrist, JA; Siddiqi, SM; Tiwari, KN | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Björck, L; Clausen, AR; Piskur, J; Sandrini, MP; Shannon, O | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
Atalay, RC; Demir, Z; Guven, EB; Kazak, C; Ozbey, S; Tuncbilek, M | 1 |
Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
Altiparmak, D; Cetin-Atalay, R; Guven, EB; Kucukdumlu, A; Tuncbilek, M | 1 |
Cheson, BD | 9 |
Elmhorn-Rosenborg, A; Juliusson, G; Liliemark, J | 1 |
Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Plunkett, W; Robertson, L | 1 |
Robak, T | 3 |
Gribbin, TE | 1 |
Hutton, JJ; Von Hoff, DD | 1 |
Ashique, A; Begleiter, A; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L | 1 |
Juliusson, G | 1 |
Dighiero, G | 2 |
Gollard, R; Lee, TC; Piro, LD; Saven, A | 1 |
Bromidge, TJ; Howe, DJ; Johnson, SA; Phillips, MJ | 1 |
Brugiatelli, M; Callea, I; Callea, V; Iacopino, P; Messina, G; Morabito, F; Nobile, F; Rodinò, A | 1 |
Hiddemann, W; Pott-Hoeck, C | 1 |
Hakimian, D; Tallman, MS | 2 |
del Giglio, A; Keating, M; O'Brien, S | 1 |
Piro, LD; Saven, A | 2 |
Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
Alexanian, R; Dimopoulos, MA; Estey, EE; Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
Saven, A | 2 |
Juliusson, G; Liliemark, J | 2 |
Piro, L; Saven, A | 1 |
Cheson, BD; Foss, FM; Sorensen, JM; Vena, DA | 1 |
Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
Bendandi, M; Buzzi, M; Farabegoli, P; Martinelli, G; Ottaviani, E; Salvucci, M; Tosi, P; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
Chubb, S; Ford, R; Hittelman, WN; Meyn, RE; Plunkett, W; Robertson, LE; Story, M | 1 |
Delannoy, A; Ferrant, A; Hanique, G | 1 |
Lemon, RH; Piro, LD; Saven, A | 1 |
Larson, RA; Spielberger, RT; Stock, W | 1 |
Beran, M; Estey, E; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Robertson, LB | 1 |
Keating, MJ; Lerner, S; O'Brien, S; Robertson, LE; Seymour, JF | 1 |
Estey, EH; Kantarjian, HM; Keating, MA | 1 |
Hapke, DM; Mitchell, BS; Stegmann, AP | 1 |
Brown, RD; Gibson, J; Joshua, DE; Luo, XF; Petersen, AJ; Pope, B; Schutz, L; Wiley, JS | 1 |
Geisen, F; Konwalinka, G; Michlmayr, G; Schirmer, M | 1 |
Faure, P; Madelaine-Chambrin, I; Piquet-Sevrin, V | 1 |
Lärfars, G; Samuelsson, J; Udén-Blohmé, AM | 1 |
Błasinka-Morawiec, M; Ceglarek, B; Dmoszynska, A; Durzynski, T; Dwilewicz-Trojaczek, J; Grieb, P; Hansz, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Kopec, I; Kotlarek-Haus, S; Krykowski, E; Lewandowski, K; Maj, S; Mazur, G; Potemski, P; Płuzanska, A; Robak, T; Sikorska, A; Skotnicki, AB; Urasinski, I; Zaucha, JM; Zdziarska, B | 1 |
Johnson, SA | 2 |
Adam, Z; Hejlová, N; Vorlícek, J | 1 |
Wiley, JS | 1 |
Baldwin, SA; Beaumont, N; Boumah, CE; Cass, CE; Coe, I; Davies, A; Griffiths, M; Kwong, FY; Sundaram, M; Yao, SY; Young, JD | 1 |
Kantarjian, H; Keating, MJ; O'Brien, S | 1 |
Gandhi, V; Plunkett, W | 1 |
Hiddemann, W; Pott, C | 1 |
Bergmann, L | 1 |
Hilgenfeld, E; Jäger, U; Knauf, WU; Mitterbauer, M; Wilfing, A | 1 |
Petryshyn, RA; Slomiany, DJ; Woldehawariat, G | 1 |
Albitar, M; Anderlini, P; Andersson, B; Beran, M; Champlin, R; Claxton, D; Estey, E; Gajewski, J; Giralt, S; Kantarjian, H; Keating, M; Khouri, I; Koller, C; Kornblau, S; Kørbling, M; Mehra, R; O'Brien, S; Przepiorka, D; Rondón, G; van Besien, K | 1 |
Cohen, JD; Katz, TB; Marcel, PD; Strock, DJ; Teik, JE | 1 |
Duley, JA; Fabianowska-Majewska, K; Ruckemann, K; Simmonds, HA | 1 |
Fabianowska-Majewska, K; Wyczechowska, D | 2 |
Bromidge, TJ; Howe, DJ; Johnson, SA; Rule, SA; Turner, DL | 1 |
Christopherson, RI; Mulligan, SP; Szabados, E; Wilson, PK | 1 |
Callea, I; Console, G; Filangeri, M; Messina, G; Morabito, F; Sculli, G | 1 |
Filangeri, M; Morabito, F; Oliva, B; Sculli, G | 1 |
Machaczka, M; Rucińska, M; Skotnicki, AB; Załuska, A | 1 |
Koski, T; Vilpo, J; Vilpo, L | 2 |
Aleskog, A; Höglund, M; Kristensen, J; Larsson, R; Sundström, C | 1 |
Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D | 1 |
Cawley, JC; Pettitt, AR; Sherrington, PD | 2 |
Cawley, JC; Clarke, AR; Griffiths, SD; Pettitt, AR | 1 |
Barrett, J; Cheson, BD; Freidlin, B; Vena, DA | 1 |
Albertioni, F; Eriksson, S; Månsson, E; Sällström, J; Spasokoukotskaja, T | 1 |
Albertioni, F; Larsson, BS; Liliemark, J; Lindemalm, S | 1 |
Honma, Y; Niitsu, N; Umeda, M | 1 |
Ahmad, I; Al-Katib, AM; Beck, FW; Liu, KZ; Mantsch, HH; Mohammad, RM; Wall, NR | 1 |
Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P | 1 |
Bosanquet, AG; Bosanquet, MI | 1 |
Kipps, TJ | 1 |
Adachi, S; Carrera, CJ; Carson, DA; Chao, Q; Cottam, HB; Genini, D; Leoni, LM; Rose, DW | 1 |
Johnson, SA; Thomas, W | 1 |
Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
Weiss, MA | 1 |
Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E | 1 |
Owen, RG | 1 |
de Frutos, MA | 1 |
Bashey, A | 1 |
Halaburda, K; Hellmann, A; Lewandowski, K | 1 |
Kasznicki, M; Robak, T | 1 |
Bosanquet, AG; Bosanquet, MI; Daniel, PT; Dörken, B; Essmann, F; Head, DJ; Sturm, I; Wieder, T | 1 |
Barlogie, B; Desikan, KR; Dhodapkar, MV | 1 |
Itälä, M; Remes, K | 1 |
Aivado, M; Burger, J; Finke, J; Haas, R; Henze, L; Schulte, K | 1 |
Gertz, MA | 2 |
Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
Albertioni, F; Elford, H; Eriksson, S; Flordal, E; Lagercrantz, S; Liliemark, J; Månsson, E; Spasokoukotskaja, T | 1 |
Glasmacher, A; Gorschlüter, M; Mey, U; Pralle, H; Schmidt-Wolf, I; Strehl, J; Ziske, C | 1 |
Byrd, JC; Larson, RA; Peterson, B; Piro, L; Saven, A; Schiffer, C; Vardiman, JW | 1 |
Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
Korycka, A; Robak, T | 2 |
Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
Pettitt, AR | 1 |
Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N | 1 |
Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K | 1 |
Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
Gartenhaus, RB; Nabhan, C; Tallman, MS | 1 |
Christopherson, RI; Mulligan, SP; Wilson, PK | 1 |
Lamanna, N; Weiss, M | 1 |
Belka, C; Daniel, PT; Dörken, B; Hasenjäger, A; Klöpfer, A; Schulze-Osthoff, K | 1 |
Aleskog, A; Höglund, M; Larsson, R; Laurell, A; Lindhagen, E; Nilsson, K; Nygren, P; Roos, G; Rosenquist, R; Sundström, C; Thunberg, U; Tobin, G | 1 |
Korycka, A; Robak, T; Smolewski, P | 1 |
Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
Dziecioł, J; Kłoczko, J; Lemancewicz, D; Piszcz, J | 1 |
Badagnani, I; Brett, CM; Burchard, EG; Carlson, EJ; Castro, RA; Chan, W; Ferrin, TE; Giacomini, KM; Huang, CC; Johns, SJ; Kawamoto, M; Stryke, D | 1 |
Badowska, W; Balcerska, A; Balwierz, W; Czyzewski, K; Debski, R; Juraszewska, E; Konatkowska, B; Kowalczyk, J; Krawczuk-Rybak, M; Kuzmicz, M; Malinowska, I; Matysiak, M; Olejnik, I; Ploszynska, A; Sońta-Jakimczyk, D; Stanczak, E; Stefaniak, J; Styczynski, J; Szczepanski, T; Wachowiak, J; Wieczorek, M; Wysocki, M | 1 |
Arbiser, J; Battle, TE; Frank, DA | 1 |
Dumontet, C; Galmarini, CM; Jordheim, LP | 1 |
Bontemps, F; Cardoen, S; Offner, F; Van den Neste, E | 1 |
Albertioni, F; Löfgren, C; Paul, C | 1 |
Cass, CE; Damaraju, VL; King, KM; Lang, T; Mowles, DA; Ng, AM; Tackaberry, TE; Vickers, MF; Yao, SY; Young, JD | 1 |
Beijnen, JH; Hillebrand, MJ; Rosing, H; Silvertand, LH; van Maanen, MJ; Vazvaei, F; Weigl, P | 1 |
Birchall, J; Johnson, SA; Luckie, C; Oscier, DG; Owen, RG | 1 |
Robak, E; Sysa-Jedrzejowska, A; Wozniacka, A | 1 |
Bohlius, J; Greil, R; Pall, G; Richards, S; Schwarzer, G; Steurer, M | 2 |
Nelson, JA; Pan, BF | 1 |
Fabianowska-Majewska, K; Krawczyk, B | 1 |
Cebula, B; Linke, A; Robak, P; Robak, T; Smolewski, P | 1 |
Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ | 1 |
Robak, P; Robak, T | 1 |
Gojkovic, Z; Hasholt, L; Joergensen, T; Knecht, W; Le Breton, C; Munch-Petersen, B; Piskur, J; Rozpedowska, E; Sandrini, MP; Willer, M | 1 |
Dabrowska, M; Dzieciol, J; Kloczko, J; Lemancewicz, D; Piszcz, JA; Rusak, M | 1 |
Fabianowska-Majewska, K; Krawczyk, B; Rudnicka, K | 1 |
Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
Bednarek, JD; Blonski, JZ; Goralski, P; Hanausek, M; Kilianska, ZM; Piekarski, H; Robak, T; Rogalinska, M; Walaszek, Z; Wozniak, K | 1 |
Berchem, G; Bouzar, AB; Boxus, M; Bron, D; Burny, A; Chatelain, B; Chatelain, C; Defoiche, J; Lagneaux, L; Macallan, D; Pettengell, R; Willems, L; Willis, F | 1 |
Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Migkou, M; Roussou, M; Tassidou, A; Terpos, E | 1 |
Castejón, R; Citores, MJ; García-Marco, JA; Vargas, JA; Villarreal, M; Yebra, M | 1 |
Błoński, JZ; Kiliańska, ZM; Robak, T; Wesierska-Gadek, J; Zolnierczyk, JD | 1 |
Beert, E; Bontemps, F; Connerotte, T; de Viron, E; Hermans, C; Knoops, L; Michaux, L; Saussoy, P; Smal, C; Van Den Neste, E; Vannuffel, P; Vekemans, MC | 1 |
Błoński, JZ; Góralski, P; Kiliańska, ZM; Komina, O; Piekarski, H; Robak, T; Rogalińska, M; Wesierska-Gadek, J; Zołnierczyk, JD | 1 |
Hoffman, PC | 1 |
Castejon, R; Citores, MJ; Garcia-Marco, JA; Rosado, S; Vargas, JA; Villarreal, M | 1 |
Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszyñska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Hellmann, A; Jamroziak, K; Konopka, L; Kostyra, A; Lewandowski, K; Piotrowska, M; Piszcz, J; Potoczek, S; Robak, T; Seferynska, I; Stella-Holowiecka, B; Warzocha, K; Zawilska, K; Zdunczyk, A | 1 |
Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M | 1 |
Bednarek, A; Fabianowska-Majewska, K; Rudnicka, K; Stefanska, B | 1 |
Chocholska, S; Dmoszynska, A; Halicka, D; Klimek, P; Kowal, M; Podhorecka, M | 2 |
Anderson, KC; Ghobrial, IM; Rourke, M | 1 |
Peinert, S; Seymour, JF | 1 |
Amsailale, R; Arts, A; Bastin-Coyette, L; Bontemps, F; Cardoen, S; de Viron, E; Smal, C; Van Den Neste, E | 1 |
Che, Y; Christopherson, RI; Henrich, S; Kohnke, PL; Mactier, S | 1 |
Tadmor, T | 1 |
Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Komina, O; Robak, P; Smolewski, P; Węsierska-Gądek, J; Żołnierczyk, JD | 1 |
Jacobson, PA; Jensen, K; Johnson, LA; Kachler, S; Kirstein, MN; Klotz, KN; Lamba, J | 1 |
Amsailale, R; Arts, A; Bontemps, F; Smal, C; Starczewska, E; Van Den Neste, E | 1 |
Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
Fathi, AT; Hasserjian, R; Sadrzadeh, H | 1 |
Borowiec, M; Błoński, JZ; Franiak-Pietryga, I; Korycka-Wołowiec, A; Maciejewski, H; Mirowski, M; Robak, T; Sałagacka, A | 1 |
Almazi, JG; Christopherson, RI; Crossett, B; Kohnke, PL; Mactier, S | 1 |
Bogusz, J; Cebula-Obrzut, B; Majchrzak, A; Mędra, A; Robak, T; Smolewski, P | 1 |
Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Kiliańska, ZM; Kotkowska, A; Robak, T; Rogalińska, M; Smolewski, P; Wawrzyniak, E; Żołnierczyk, JD | 1 |
Daly, A; Kangarloo, SB; Ng, ES | 1 |
Brandberg, Y; Gill, D; Hammerström, J; Hertzberg, M; Johansson, H; Juliusson, G; Jønsson, V; Karlsson, K; Liliemark, J; McLennan, R; Mulligan, SP; Norman, J; Strömberg, M; Sundström, G; Uggla, B; Wallvik, J | 1 |
Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
Błoński, JZ; Góralski, P; Hartman, M; Kiliańska, ZM; Koceva-Chyła, A; Piekarski, H; Robak, P; Robak, T; Rogalińska, M; Rogalska, A; Wawrzyniak, E | 1 |
Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
Brennig, S; Czarnecki, K; Dilloo, D; Heinz, N; Heise, M; Heuser, M; Kaever, V; Kempf, H; Lachmann, N; Moritz, T; Phaltane, R; Schambach, A | 1 |
Baranovsky, A; Bogushevich, S; Golubeva, M; Kalinichenko, E; Kulak, T; Kuzmitsky, B; Tsybulskaya, I | 1 |
Treon, SP | 1 |
Byrne, WL; Cummins, J; Lehouritis, P; McCarthy, FO; Murphy, CT; Reid, G; Stanton, M; Tangney, M; Urbaniak, C | 1 |
Goto, H; Goto, S; Yokosuka, T | 1 |
Aye, Y; Blessing, WA; Fletcher, EA; Li, M; Long, MJ; Weiss, RS; Wisitpitthaya, S; Zhao, Y | 1 |
Arana Echarri, A; Beyaert, M; Bol, V; Bontemps, F; Michaux, L; Saussoy, P; Smal, C; Starczewska, E; Van Den Neste, E; Vekemans, MC | 1 |
Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
Cros-Perrial, E; Dumontet, C; Jordheim, LP; Lefebvre-Tournier, I; Peyrottes, S; Puy, JY | 1 |
Chua, KYL; Holmes, NE; Meher-Homji, Z; Phillips, EJ; Seymour, JF; Siderov, J; Slavin, MA; Tam, CS; Trubiano, JA | 1 |
Atalay, RC; Guven, EB; Kucukdumlu, A; Tuncbilek, M | 1 |
DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
62 review(s) available for fludarabine and cladribine
Article | Year |
---|---|
New antimetabolites in the treatment of human malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Clinical Trials as Topic; Drugs, Investigational; Forecasting; Humans; Immunosuppression Therapy; Leukemia; Lymphoma; Pentostatin; Purines; Vidarabine | 1992 |
[New analogs of deoxyadenosine for treatment of lymphoid malignancies].
Topics: Antineoplastic Agents; Cladribine; Deoxyadenosines; Formycins; Humans; Leukemia; Lymphoma; Vidarabine | 1992 |
New purine analogues for the treatment of chronic B-cell malignancies.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1991 |
Immunological and genetic abnormalities in chronic lymphocytic leukaemia. Impact of the purine analogues.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Cladribine; Humans; Immunity, Cellular; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1994 |
Potential immunological action of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cladribine; Humans; Immunosuppressive Agents; Leukemia; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
The optimal management of hairy cell leukaemia.
Topics: Antineoplastic Agents; Cladribine; Combined Modality Therapy; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Leukemia, Hairy Cell; Pentostatin; Splenectomy; Vidarabine | 1995 |
Infectious and immunosuppressive complications of purine analog therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Humans; Immune Tolerance; Infections; Pentostatin; Purines; Vidarabine | 1995 |
Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 1995 |
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance; Humans; Lymphoproliferative Disorders; Pentostatin; Purine Nucleosides; Vidarabine | 1995 |
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine | 1995 |
The newer purine analogs. Significant therapeutic advance in the management of lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma; Pentostatin; Vidarabine | 1993 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia; Lymphoma; Molecular Structure; Pentostatin; Purine Nucleosides; Vidarabine | 1993 |
Neurotoxicity of purine analogs: a review.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Male; Middle Aged; Nervous System; Nervous System Diseases; Pentostatin; Purine Nucleosides; Vidarabine | 1994 |
Nucleoside analogs in treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Survival Rate; Vidarabine | 1993 |
New chemotherapeutic agents in acute myeloid leukemia.
Topics: Acute Disease; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotoxins; Leukemia, Myeloid; Oligonucleotides, Antisense; Retinoids; Vidarabine | 1996 |
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Vidarabine | 1996 |
The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia.
Topics: Alkylation; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1996 |
[Current therapeutic methods in onco-hematology].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cladribine; Docetaxel; Humans; Keratolytic Agents; Leukemia; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tretinoin; Vidarabine | 1996 |
Purine analogues in the management of lymphoproliferative diseases.
Topics: Antineoplastic Agents; Cladribine; Humans; Lymphoproliferative Disorders; Pentostatin; Vidarabine | 1996 |
[Treatment of chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Vidarabine | 1996 |
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purine Nucleosides; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
2-Chlorodeoxyadenosine treatment of lymphoma.
Topics: Adenosine Deaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell, Cutaneous; Pentostatin; Vidarabine; Waldenstrom Macroglobulinemia | 1996 |
Pharmacology of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Adverse and beneficial immunological effects of purine nucleoside analogues.
Topics: Animals; Antineoplastic Agents; Cladribine; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Purine Nucleosides; Vidarabine | 1996 |
Perspectives on purine analogues.
Topics: Antineoplastic Agents; Cladribine; Forecasting; Humans; Leukemia; Pentostatin; Purines; Vidarabine | 1996 |
Purine analogs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1997 |
Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prognosis; Recurrence; Remission Induction; Vidarabine | 1997 |
Is there a place for 2-CDA in the treatment of B-CLL?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Recurrence; Thrombocytopenia; Vidarabine | 1997 |
Therapy for previously untreated chronic lymphocytic leukemia: a reevaluation.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 1998 |
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Pentostatin; Remission Induction; Splenectomy; Vidarabine | 1998 |
Chronic lymphocytic leukemia.
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; CD79 Antigens; Chromosome Aberrations; Chromosomes, Human; Cladribine; Combined Modality Therapy; Cytokines; Female; Genes, Immunoglobulin; Genes, p53; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Deficiency Syndromes; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplastic Stem Cells; Prognosis; Risk Factors; Vidarabine | 2000 |
Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Purines; Vidarabine | 2000 |
Novel treatment strategies in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pentostatin; Randomized Controlled Trials as Topic; Sex Factors; Vidarabine | 2001 |
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Topics: Alkylating Agents; Antimetabolites; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Guidelines as Topic; Humans; Middle Aged; Pentostatin; Plasmapheresis; Purine Nucleosides; Quality of Life; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.
Topics: Animals; Antibodies, Monoclonal; Antilymphocyte Serum; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Pentostatin; Transplantation, Homologous; Vidarabine | 2002 |
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine | 2002 |
Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
[Nucleoside analogues--new drugs for the treatment of lymphatic cancers].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphoid; Lymphoma; Nucleosides; Pentostatin; Vidarabine | 2001 |
Waldenström's macroglobulinemia: a review of therapy.
Topics: Adrenal Cortex Hormones; Alkylating Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Hematopoietic Stem Cell Transplantation; Humans; Plasma Exchange; Rituximab; Splenectomy; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
Advances in the treatment of hairy-cell leukaemia.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Cell Adhesion Molecules; Cladribine; Humans; Interferon-alpha; Lectins; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplasms, Second Primary; Pancytopenia; Pentostatin; Receptors, Interleukin-2; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Spleen; Splenectomy; Splenomegaly; Treatment Outcome; Vidarabine | 2003 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cladribine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Phosphorylation; Tumor Suppressor Protein p53; Vidarabine | 2003 |
Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Rituximab; Vidarabine | 2004 |
Purine analogs in leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Pentostatin; Purines; Stem Cell Transplantation; Vidarabine | 2004 |
Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; CD52 Antigen; Cladribine; Clinical Trials as Topic; Glycoproteins; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Random Allocation; Rituximab; Time Factors; Vidarabine | 2005 |
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine | 2005 |
Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review).
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Membrane; Cell Proliferation; Cell Survival; Cladribine; DNA; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Models, Biological; Models, Chemical; Nucleosides; RNA; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2005 |
Guidelines on the management of Waldenström macroglobulinaemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cladribine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Immunologic Factors; Immunosuppressive Agents; Plasma Exchange; Prognosis; Rituximab; Stem Cell Transplantation; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
[Progress and perspectives in the treatment of systemic lupus erythematosus].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Antineoplastic Agents, Alkylating; Azathioprine; Cladribine; Cyclophosphamide; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mycophenolic Acid; Vidarabine | 2005 |
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis.
Topics: Anemia, Hemolytic; Antineoplastic Agents; Cladribine; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2006 |
Purine antagonists for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Chlorambucil; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 2006 |
Current treatment options in prolymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Drug Therapy; Humans; Leukemia, Prolymphocytic; Pentostatin; Purine Nucleosides; Rituximab; Splenectomy; Stem Cell Transplantation; Vidarabine | 2007 |
Rituximab-based treatments in Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Humans; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
Immune hemolytic anemia--selected topics.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Group Incompatibility; Cladribine; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Subsets; Lymphoproliferative Disorders; Postoperative Complications; Rituximab; Splenectomy; Transfusion Reaction; Transplantation; Transplantation, Homologous; Venous Thromboembolism; Vidarabine | 2009 |
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Purine analog toxicity in patients with hairy cell leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Purines; Vidarabine | 2011 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
17 trial(s) available for fludarabine and cladribine
Article | Year |
---|---|
Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: 2-Chloroadenosine; Adult; Antineoplastic Agents; Cladribine; Deoxyadenosines; Drug Resistance; Female; Haptoglobins; Humans; Immunoglobulins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphocytes; Male; Middle Aged; Remission Induction; Vidarabine | 1992 |
Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Humans; Middle Aged; Remission Induction; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 1993 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1993 |
Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.
Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Cladribine; Combined Modality Therapy; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Survival Analysis; Vidarabine | 1995 |
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Vidarabine | 1996 |
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Combined Modality Therapy; Cytarabine; Feasibility Studies; Female; Filgrastim; Graft vs Host Reaction; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Recombinant Proteins; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 1997 |
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2000 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Confidence Intervals; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Patient Selection; Survival Rate; Time Factors; Vidarabine | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Cytogenetic Analysis; Female; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2010 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
In vivo and ex vivo responses of CLL cells to purine analogs combined with alkylating agent.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cladribine; Cyclophosphamide; DNA Fragmentation; Electrophoresis, Agar Gel; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Vidarabine | 2013 |
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Treatment Outcome; Vidarabine | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Treatment Outcome; Vidarabine | 2015 |
124 other study(ies) available for fludarabine and cladribine
Article | Year |
---|---|
Synthesis and biologic activity of 2'-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine.
Topics: Animals; Antimetabolites, Antineoplastic; Escherichia coli; HIV; Humans; Leukemia P388; Mice; Purine-Nucleoside Phosphorylase; Structure-Activity Relationship; Tumor Cells, Cultured; Vidarabine | 1992 |
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
Topics: Adenosine; Animals; Cell Membrane; CHO Cells; Corpus Striatum; Cricetinae; In Vitro Techniques; Magnetic Resonance Spectroscopy; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Radioligand Assay; Rats; Recombinant Proteins; Ribose; Structure-Activity Relationship | 1995 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
Topics: Animals; Anti-Bacterial Agents; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleosides; Phosphotransferases (Alcohol Group Acceptor); Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.
Topics: Antineoplastic Agents; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Models, Molecular; Molecular Structure; Purines; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Synthesis of novel 6-substituted amino-9-(β-d-ribofuranosyl)purine analogs and their bioactivities on human epithelial cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purine Nucleosides; Vidarabine | 2018 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
The purine analogs--a therapeutic beauty contest.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Deoxyadenosines; Humans; Leukemia; Pentostatin; Vidarabine | 1992 |
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.
Topics: 2-Chloroadenosine; Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1992 |
New drugs in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Vidarabine | 1992 |
Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay.
Topics: Cell Survival; Cells, Cultured; Cladribine; Colony-Forming Units Assay; Deoxyadenosines; Drug Evaluation, Preclinical; Female; Humans; Kinetics; Neoplasms; Vidarabine | 1986 |
Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
Topics: Antineoplastic Agents; Biological Transport; Bone Marrow; Cell Survival; Cells, Cultured; Chlorambucil; Cladribine; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1995 |
Adaptation of the TdT assay for semi-quantitative flow cytometric detection of DNA strand breaks.
Topics: Antineoplastic Agents; Apoptosis; Cells, Cultured; Cladribine; DNA Damage; DNA Nucleotidylexotransferase; Flow Cytometry; Humans; Lymphocytes; Ultraviolet Rays; Vidarabine | 1995 |
Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Humans; Interferon-alpha; Interleukin-1; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Necrosis Factor-alpha; Vidarabine | 1995 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
2-Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1994 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells.
Topics: Aged; Apoptosis; Cladribine; DNA Damage; Female; Humans; In Vitro Techniques; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pentostatin; Tumor Cells, Cultured; Vidarabine | 1994 |
Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2'-deoxyadenosine and 9-beta-D-arabinosyl-2-fluoroadenine.
Topics: Adenosine Triphosphate; Apoptosis; Cladribine; Cycloheximide; Dactinomycin; DNA, Neoplasm; Egtazic Acid; Guanosine Triphosphate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Microscopy, Electron; Puromycin; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Uridine Triphosphate; Vidarabine | 1993 |
2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine.
Topics: Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1993 |
Listeriosis after 2-chlorodeoxyadenosine treatment.
Topics: Aged; Antineoplastic Agents; Cladribine; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Vidarabine | 1993 |
Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biotransformation; Breast Neoplasms; Carcinoma, Small Cell; Cladribine; Colonic Neoplasms; Cytarabine; Deoxycytidine Kinase; DNA, Complementary; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Genetic Vectors; Humans; Lung Neoplasms; Moloney murine leukemia virus; Phosphorylation; Recombinant Fusion Proteins; Tumor Cells, Cultured; Vidarabine | 1996 |
Nucleoside transporters, bcl-2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro.
Topics: Antigens, CD19; Apoptosis; B-Lymphocytes; Carrier Proteins; CD5 Antigens; Cladribine; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Neoplasm Proteins; Nucleoside Transport Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured; Vidarabine | 1996 |
2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?
Topics: Antineoplastic Agents; Cladribine; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 1996 |
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Count; Cladribine; Combined Modality Therapy; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Opportunistic Infections; Remission Induction; Retreatment; Survival Rate; Treatment Outcome; Vidarabine | 1996 |
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine | 1996 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs.
Topics: Adenosine; Amino Acid Sequence; Animals; Antineoplastic Agents; Carrier Proteins; Cladribine; Cloning, Molecular; Cytarabine; Databases, Factual; DNA, Complementary; Equilibrative Nucleoside Transporter 1; Humans; Membrane Proteins; Molecular Sequence Data; Nucleosides; Oocytes; Recombinant Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Tissue Distribution; Uridine; Vidarabine; Xenopus | 1997 |
Chemotherapeutic purine analogs alter the level of interferon-beta mRNA induced by poly I-poly C in cultured osteosarcoma cells.
Topics: Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; eIF-2 Kinase; Gene Expression; Humans; Interferon-beta; Neoplastic Stem Cells; Pentostatin; Poly I-C; Protein Serine-Threonine Kinases; RNA, Messenger; Vidarabine | 1997 |
Deoxycytidine in human plasma: potential for protecting leukemic cells during chemotherapy.
Topics: Adult; Cladribine; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Effect of Cladribine, fludarabine, and 5-aza-deoxycytidine on S-adenosylmethionine (SAM) and nucleotides pools in stimulated human lymphocytes.
Topics: Adenine Nucleotides; Adenine Phosphoribosyltransferase; Antineoplastic Agents; Azacitidine; Cells, Cultured; Cladribine; Cytidine Triphosphate; Decitabine; Guanine Nucleotides; Humans; Kinetics; Lymphocyte Activation; Lymphocytes; NAD; Ribonucleotides; S-Adenosylmethionine; Uracil Nucleotides; Vidarabine | 1998 |
Does 2-chlorodeoxyadenosine contribute to alteration of DNA methyltransferase activity?
Topics: Adenosylhomocysteinase; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cladribine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Hydrolases; Kinetics; Leukemia L1210; Mice; Tumor Cells, Cultured; Vidarabine | 1998 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues--correlation with clinical course.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA Nucleotidylexotransferase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Phenotype; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1998 |
Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines.
Topics: Adenosine Deaminase Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Division; Cladribine; Deoxyribonucleotides; Enzyme Inhibitors; Humans; Kinetics; Leukemia, T-Cell; Lymphoma, B-Cell; Pentostatin; Ribonucleotides; Tumor Cells, Cultured; Vidarabine | 1998 |
Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine | 1998 |
In vitro modulation of bcl-2 protein expression, drug-induced apoptosis and cytotoxicity by interleukin-10 in chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Drug Interactions; Drug Screening Assays, Antitumor; Gene Expression Regulation, Leukemic; Humans; Interleukin-10; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 1998 |
Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Cells, Cultured; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1999 |
Evaluation of purine and pyrimidine analogues in human tumor cells from patients with low-grade lymphoproliferative disorders using the FMCA.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Cytarabine; Fluorescence; Fluorometry; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Lymphoma, Non-Hodgkin; Survival Analysis; Vidarabine | 1999 |
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine | 1999 |
The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Survival; Cladribine; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Cells, Cultured; Vidarabine | 1999 |
Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms.
Topics: Animals; Cell Death; Cladribine; Coformycin; Dexamethasone; Drug Resistance; Etoposide; Genes, p53; Lymphocytes; Mice; Mice, Knockout; Spleen; Vidarabine | 1999 |
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Vidarabine | 1999 |
Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
Topics: Antineoplastic Agents; Biological Transport; Biotransformation; Cell Survival; Cladribine; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Phosphorylation; Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Vidarabine | 1999 |
Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Autoradiography; Brain; Cladribine; Clofarabine; Cytarabine; Lipid Metabolism; Mice; Mice, Inbred C57BL; Thymus Gland; Tissue Distribution; Tritium; Vidarabine | 1999 |
Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.
Topics: Acute Disease; Adenosine Deaminase Inhibitors; Antimetabolites, Antineoplastic; Calcitriol; Cell Differentiation; Cladribine; Deoxyadenosines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Monocytes; Neoplasm Proteins; Neoplastic Stem Cells; Pentostatin; Tretinoin; Tumor Cells, Cultured; U937 Cells; Vidarabine | 2000 |
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Topics: Aged; Antineoplastic Agents; Biological Transport, Active; Bryostatins; Carrier Proteins; Cladribine; Deoxycytidine Kinase; Dipyridamole; Down-Regulation; Drug Resistance, Neoplasm; Humans; Lactones; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Membrane Proteins; Nucleoside Transport Proteins; Phosphorylation; Thioinosine; Tumor Cells, Cultured; Vidarabine | 2000 |
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine | 2000 |
Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium; Calcium Channel Blockers; Calcium Signaling; Chlorambucil; Cisplatin; Cladribine; Cyclosporine; DNA Fragmentation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nifedipine; Prednisolone; Tumor Cells, Cultured; Verapamil; Vidarabine; Vincristine | 2000 |
Role of poly(ADP-ribosyl)ation in the killing of chronic lymphocytic leukemia cells by purine analogues.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Membrane; Cell Size; Cladribine; DNA Fragmentation; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53; Vidarabine | 2000 |
Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Arabinonucleosides; B-Lymphocytes; Cell Survival; Cladribine; Clofarabine; Comet Assay; Deoxyadenosines; DNA Damage; DNA, Mitochondrial; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Potentials; Microinjections; Mitochondria; Time Factors; Tumor Cells, Cultured; Vidarabine | 2000 |
[Lupus nephritis: treatments for today and tomorrow].
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; CD40 Ligand; Cladribine; Drug Administration Schedule; Drug Therapy, Combination; Forecasting; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid; Oligonucleotides; Plasmapheresis; Vidarabine | 2001 |
Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.
Topics: Aged; Cladribine; Drug Evaluation; Humans; Immunoglobulin M; Immunosuppressive Agents; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2002 |
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Chlorambucil; Cladribine; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Cladribine; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Salvage Therapy; Vidarabine | 2002 |
The effects of cladribine and fludarabine on DNA methylation in K562 cells.
Topics: Adenosine; Antineoplastic Agents; Cell Survival; Cladribine; CpG Islands; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Gene Silencing; Humans; K562 Cells; Tumor Cells, Cultured; Vidarabine | 2003 |
Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cell Line; Cladribine; Clofarabine; Cytogenetics; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Leukemia; Phenotype; Phosphorylation; Ribonucleotide Reductases; Vidarabine | 2003 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Colony-Forming Units Assay; Cyclosporine; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Vidarabine | 2003 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2004 |
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Ionomycin; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nucleotides; Pentostatin; Prognosis; Tumor Cells, Cultured; Vidarabine | 2004 |
Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Caspase 8; Caspases; Cell Line, Tumor; Cladribine; Fas-Associated Death Domain Protein; Humans; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2004 |
VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cladribine; Cyclophosphamide; Cytarabine; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Genes, Immunoglobulin; Humans; Idarubicin; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Melphalan; Prednisolone; Survival Analysis; Vidarabine; Vincristine | 2004 |
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Leukemia, Myeloid; Male; Middle Aged; Quinolones; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine | 2004 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Vidarabine | 2004 |
Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3).
Topics: Adenosine; Animals; Antineoplastic Agents; Cation Transport Proteins; Cladribine; Conserved Sequence; DNA; Ethnicity; Genetic Variation; Haplotypes; Humans; Membrane Transport Proteins; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Oocytes; Vidarabine; Xenopus laevis | 2005 |
In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
Topics: Adolescent; Adult; Antineoplastic Agents; Cell Death; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Tumor Cells, Cultured; Vidarabine | 2005 |
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Caspases; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; In Vitro Techniques; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lignans; Magnolia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Biological Transport; Cell Line; Cladribine; Clofarabine; Humans; Membrane Transport Proteins; Recombinant Proteins; Vidarabine; Xenopus laevis | 2006 |
Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cladribine; Cyclophosphamide; Humans; Molecular Structure; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Vidarabine | 2005 |
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cladribine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Kidney Neoplasms; Oxidoreductases; Transfection; Vidarabine | 2007 |
Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues.
Topics: Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; Estrogen Receptor alpha; Genes, APC; Genes, BRCA1; Humans; K562 Cells; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Vidarabine | 2006 |
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cladribine; Etodolac; Humans; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Purines; Rituximab; Spectrometry, Fluorescence; Vidarabine | 2006 |
Drosophila deoxyribonucleoside kinase mutants with enhanced ability to phosphorylate purine analogs.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cytarabine; Directed Molecular Evolution; Drosophila melanogaster; Genes, Transgenic, Suicide; Genetic Therapy; Glioblastoma; Humans; Lethal Dose 50; Mutation; Neoplasms; Osteosarcoma; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Purines; Substrate Specificity; Transduction, Genetic; Vidarabine | 2007 |
Cannabinoid receptors expression in bone marrow trephine biopsy of chronic lymphocytic leukaemia patients treated with purine analogues.
Topics: Antineoplastic Agents; B-Lymphocytes; Biopsy; Bone Marrow Cells; Cladribine; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Purines; Receptors, Cannabinoid; Vidarabine | 2007 |
The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cladribine; Decitabine; DNA Methylation; DNA, Neoplasm; Female; Genes, APC; Genes, BRCA1; Genes, Tumor Suppressor; Humans; Nucleosides; Promoter Regions, Genetic; PTEN Phosphohydrolase; Receptors, Retinoic Acid; Vidarabine | 2007 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calorimetry, Differential Scanning; Cell Survival; Cells, Cultured; Cladribine; Cyclophosphamide; DNA Damage; Drug Combinations; Drug Monitoring; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myeloid Cell Leukemia Sequence 1 Protein; Phase Transition; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2009 |
Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Blotting, Western; Cladribine; Drug Synergism; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Confocal; Middle Aged; Reactive Oxygen Species; Tumor Cells, Cultured; Valproic Acid; Vidarabine | 2009 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Chlorambucil; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prognosis; Time Factors; Tumor Cells, Cultured; Vidarabine | 2009 |
Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cell Survival; Cells, Cultured; Cladribine; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclophosphamide; Drug Synergism; Female; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Purines; Roscovitine; Vidarabine | 2009 |
Impaired up-regulation of polo-like kinase 2 in B-cell chronic lymphocytic leukaemia lymphocytes resistant to fludarabine and 2-chlorodeoxyadenosine: a potential marker of defective damage response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Death; Cladribine; Cohort Studies; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2009 |
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Survival; Cells, Cultured; Cladribine; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Cyclophosphamide; Female; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Purines; Roscovitine; Vidarabine | 2010 |
CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Autoimmunity; CD40 Ligand; Cells, Cultured; Cladribine; Female; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Vidarabine | 2010 |
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells.
Topics: Adenosine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cholecalciferol; Cladribine; DNA Methylation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Promoter Regions, Genetic; Receptors, Retinoic Acid; Resveratrol; Stilbenes; Transcriptional Activation; Tretinoin; Vidarabine | 2010 |
Simvastatin and purine analogs have a synergic effect on apoptosis of chronic lymphocytic leukemia cells.
Topics: ADP-ribosyl Cyclase 1; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Simvastatin; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
Resveratrol increases rate of apoptosis caused by purine analogues in malignant lymphocytes of chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Proteins; Cladribine; DNA-Binding Proteins; Drug Therapy, Combination; Enzyme Activation; Histones; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Membrane Glycoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Purines; Resveratrol; Stilbenes; Tumor Suppressor Proteins; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2011 |
What's new in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Nucleoside analogs induce proteasomal down-regulation of p21 in chronic lymphocytic leukemia cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Enzyme Activation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proliferating Cell Nuclear Antigen; Proteasome Endopeptidase Complex; Purine Nucleosides; Tumor Suppressor Protein p53; Ubiquitination; Up-Regulation; Vidarabine | 2011 |
Comprehensive proteomic analysis of the effects of purine analogs on human Raji B-cell lymphoma.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cladribine; Electrophoresis, Gel, Two-Dimensional; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Humans; Lymphoma, B-Cell; Mitochondria; Molecular Chaperones; Proteome; Purines; Vidarabine | 2011 |
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Purines; Roscovitine; Vidarabine | 2012 |
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Binding, Competitive; CHO Cells; Cladribine; Clofarabine; Cricetinae; Cricetulus; Cytotoxins; Humans; Purinergic P1 Receptor Agonists; Radioligand Assay; Receptors, Purinergic P1; Vidarabine | 2012 |
Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Topics: Antineoplastic Agents; Aphidicolin; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Enzyme Activation; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Kinetics; Mutation; Phosphorylation; Purine Nucleosides; Pyrimidine Nucleosides; Serine; Structure-Activity Relationship; Substrate Specificity; Vidarabine | 2012 |
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia.
Topics: Abnormal Karyotype; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Fatal Outcome; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Prednisone; Vidarabine; Vincristine | 2013 |
Apoptotic gene expression under influence of fludarabine and cladribine in chronic lymphocytic leukemia-microarray study.
Topics: Antineoplastic Agents; Apoptosis; Cladribine; DNA, Complementary; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Transcriptome; Tumor Cells, Cultured; Vidarabine | 2012 |
Fludarabine and cladribine induce changes in surface proteins on human B-lymphoid cell lines involved with apoptosis, cell survival, and antitumor immunity.
Topics: Antigens, CD; Apoptosis; B-Lymphocytes; Burkitt Lymphoma; Cell Adhesion; Cell Line; Cell Line, Tumor; Cell Survival; Cladribine; Drug Resistance, Neoplasm; Flow Cytometry; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Proteins; Reproducibility of Results; Signal Transduction; Up-Regulation; Vidarabine | 2012 |
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Caspase 3; Caspase 9; Cladribine; Cyclophosphamide; Down-Regulation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proteasome Inhibitors; Rituximab; Sirolimus; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vidarabine | 2013 |
Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Cladribine; Drug Stability; Humans; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vidarabine | 2013 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
Deoxycytidine-kinase knockdown as a novel myeloprotective strategy in the context of fludarabine, cytarabine or cladribine therapy.
Topics: Antineoplastic Agents; Bone Marrow; Cladribine; Cytarabine; Cytidine Deaminase; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Genetic Therapy; Hematopoietic Stem Cell Transplantation; HL-60 Cells; Humans; Vidarabine | 2015 |
Phospholipid derivatives of cladribine and fludarabine: synthesis and biological properties.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Diglycerides; Humans; Male; Mice; Mice, Inbred ICR; Molecular Structure; Organophosphonates; Phospholipids; Prodrugs; Rats; Rats, Wistar; Vidarabine | 2015 |
How I treat Waldenström macroglobulinemia.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Cyclophosphamide; Everolimus; Gene Expression; Genetic Predisposition to Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin M; Male; Middle Aged; Molecular Targeted Therapy; Myeloid Differentiation Factor 88; Nitrogen Mustard Compounds; Oligopeptides; Piperidines; Plasmapheresis; Pyrazines; Pyrazoles; Pyrimidines; Receptors, CXCR4; Rituximab; Sirolimus; Transplantation, Autologous; Vidarabine; Waldenstrom Macroglobulinemia | 2015 |
Local bacteria affect the efficacy of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Cladribine; Colonic Neoplasms; Deoxycytidine; Escherichia coli; Female; Gemcitabine; Injections, Intralesional; Injections, Subcutaneous; Listeria; Mice; Neoplasm Transplantation; Skin; Treatment Outcome; Vidarabine | 2015 |
The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells.
Topics: Adenine Nucleotides; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Child; Cladribine; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Synergism; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 2016 |
Cladribine and Fludarabine Nucleotides Induce Distinct Hexamers Defining a Common Mode of Reversible RNR Inhibition.
Topics: Biopolymers; Chromatography, Gel; Cladribine; Fluorescence Polarization; Nucleotides; Ribonucleotide Reductases; Vidarabine | 2016 |
Targeting DNA repair with aphidicolin sensitizes primary chronic lymphocytic leukemia cells to purine analogs.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cladribine; DNA Damage; DNA Repair; Drug Synergism; Enzyme Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cladribine; Clofarabine; Humans; Limit of Detection; Neoplasms; Polyphosphates; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Vidarabine | 2017 |
High prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribing.
Topics: Adult; Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Australia; Case-Control Studies; Cladribine; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Prevalence; Prognosis; Retrospective Studies; Survival Rate; Vidarabine | 2019 |
Design, Synthesis and In Vitro Cytotoxic Activity of New 6,9-Disubstituted Purine Analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cladribine; Drug Design; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Molecular Structure; Purines; Vidarabine | 2020 |